Kornimate/medical-research-clean huggingface dataset:
dexmedetomidine for catheter-related bladder discomfort

Conditions: Pain; Blood Pressure; Nausea; Vomiting; Arrhythmia

Summary: to evaluate the efficacy of dexmedetomidine for the prevention of catheter-related bladder discomfort

after transurethral bladder resection, large-sized foley catheter have been used for drainage of urine and residual blood. because of urinary catheterization, patients usually experiences catheter-related bladder discomfort defined as a burning sensation with an urge to void or discomfort in the supra-pubic region caused by catheter- related bladder irritation. dexmedetomidine is an alpha-2 antagonist and used as an analgesic agent. the investigators try to evaluate the efficacy of dexmedetomidine for the treatment of catheter-related bladder discomfort

Eligibility criteria:
inclusion criteria: * patients scheduled for transurethral bladder resection * asa i-iii exclusion criteria: * patient who disagrees to participate this investigation * patient with severe cardiovascular disease * patient with small-sized foley catheter (less than 18 fr.) * patinets with any urinary tract obstructions * patient with hyperactive or neurogenic bladder * patients with chronic renal failure * patient with morbidly obese * patients with neurogenic disorder * patient with medications for chronic pain
a phase iii study of esg401 for unresectable recurrent or metastatic triple-negative breast cancer

Conditions: Triple-Negative Breast Cancer (TNBC)

Summary: the aim of this study is to evaluate the efficacy and safety of esg401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.

this is a randomized, open-label, multicenter phase 3 study to evaluate esg401 versus investigator's choice chemotherapy (icc) as first-line treatment in subjects with unresectable recurrent or metastatic triple-negative breast cancer.

Eligibility criteria:
key inclusion criteria: 1. males or females aged ≥ 18 years ; 2. histologically and/or cytologically confirmed tnbc; 3. de novo metastatic or relapsed ≥ 6 months post completion of treatment with curative intent; 4. no prior systemic anti-cancer therapy for unresectable recurrent or metastatic disease; 5. participants whose tumours are pd-l1-negative, or participants whose tumours are pd-l1-positive and have relapsed after prior pd-1/pd-l1 inhibitor therapy for early-stage breast cancer, or comorbidities precluding pd-1/pd-l1 inhibitor therapy; 6. eligible for the chemotherapy options listed as investigator's choice chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin) as assessed by the investigator; 7. at least one measurable lesion per recist v1.1; 8. eastern cooperative oncology group (ecog) performance status of 0 to 1 with no worsening within 2 weeks prior to randomization; 9. a life expectancy of at least 12 weeks; 10. adequate organ and bone marrow function. key exclusion criteria: 1. use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration. 2. toxicities from prior anti-tumor therapy not recovering to ≤ grade 1. 3. prior topoisomerase i inhibitor therapy, including antibody-drug conjugate(adc) therapy, or prior trop2 targeted therapy. 4. new thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months. 5. subjects with symptomatic or untreated cns metastases, or those requiring ongoing treatment for cns metastases. 6. patients with primary cns malignancy, or patients with other malignancies within 3 years prior to the first dose. 7. patients with uncontrollable systemic diseases. 8. patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea. 9. subjects with clinically significant cardiovascular disease. 10. human immunodeficiency virus (hiv) infection. 11. active hepatitis b or hepatitis c. 12. known immediate or delayed hypersensitivity reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or excipient ingredient. 13. pregnant or lactating women.
ultra-sensitivity quantitative fecal immunochemical test in detecting colorectal advanced adenoma and colorectal cancer

Conditions: Colorectal Neoplasm

Summary: early detecting and removing of colorectal advanced adenomas can reduce the incidence of colorectal cancer. because of the less bleeding of advanced adenomas, sensitivities of the common used quantitative fecal immunochemical tests (qfits) are unsatisfying. ultra-sensitivity qfit(us-qfit) can determine extremely low fecal hemoglobin concentration compared with the common used qfit. this study will prove the diagnostic accuracy of us-qfit in detecting colorectal advanced adenomas.

early detection of crc in a curable stage can reduce mortality but not morbidity. the majority of colorectal cancer is thought to arise from precancerous lesions through the adenoma-carcinoma pathway. detecting and removing of colorectal advanced adenomas can reduce incidence of colorectal cancer. although colonoscopy is currently considered the most effective method for detecting advanced adenomas, individuals may be reluctant to undergo colonoscopy due to the uncomfortable feeling and the relatively high cost. conversely, stool tests are relatively cheap and more readily accepted. fecal immunochemical test (fit) is economic and easy to use in colorectal cancer screening. however, the common used qfit is insufficiently sensitive to the minor hemorrhage of advanced adenomas, and the sensitivity is about only 27% to 47%. to improve the detection rate of colorectal advanced adenoma, ultra-sensitivity quantitative fecal immunochemical test (us-qfit) improves technology and can detect fecal hemoglobin in extremely low concentration quantificationally. the investigators design this research to prove the diagnostic accuracy of us-qfit in detecting colorectal advanced adenoma.

Eligibility criteria:
inclusion criteria: * 50-75 years old people; * people sign an "informed consent form" exclusion criteria: * people with history of colorectal surgery; * people with history of colorectal cancer; * people with history of other diseases that may produce fecal blood, such as inflammatory bowel disease, ischemic enteritis, vascular alformation of intestine, intestinal tuberculosis or non-hodgkin's lymphoma involving digestive tract; * people with symptoms including visible rectal bleeding, hematuria, hemorrhoid bleeds, severe and acute diarrhea and watery stool; * people are in pregnancy, lactation or menstrual phase; * people with severe congestive heart failure or other sever disease cause cannot tolerate colonoscopy.

Keywords: colorectal neoplasm occult bleeding quantitative fecal immunochemical test colorectal cancer adenoma
use of proteomics for the diagnosis of a platelet-related bleeding disorder

Conditions: Inherited Platelet Disorders

Summary: the goal of this study is to identify the platelet defect responsible for the bleeding in families from our inherited platelet disorders israeli-palestinian registry. the investigators plan to characterize platelet proteome expression after removing high abundance proteins. the investigators will compare the proteome of sick and healthy members of families with inherited platelet disorders, and identify and validate structural proteins, signaling cascades and biomarkers for detection and diagnosis of unknown platelet disorders. the investigators expect to discover new key findings that allow better understanding of human platelet function and allow better diagnosis and treatment of patients with inherited platelet function disorders.


Eligibility criteria:
inclusion criteria: * history of inherited platelet disorders in the family exclusion criteria: * none

Keywords: inherited platelet disorders proteome
intraductal papillary mucinous neoplasm (ipmn) database - a tool to predict pancreatic cancer

Conditions: IPMN, Pancreatic; IPMN

Summary: pancreatic cancer is the 5th leading cause of cancer death in australia. surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure. unfortunately, many patients present with advanced disease and are not suitable for surgery. therefore, it is vital to detect these cancers early. in the absence of significant data from prospective studies, all of the guidelines are based on a critical review of available data and consensus of experts. the primary aim is to delineate the progression of ipmn to pancreatic malignancy as confirmed by surgical pathology, radiology and biochemical diagnosis. the secondary aims are (i) to outline the management of ipmns for those who have progressed straight to surgery or surveillance by endoscopic ultrasound (eus) (ii)to validate the international consensus guidelines for management of ipmn - fukuoka consensus guidelines and tertiary aim to identify potential risk factors, if any that increase risk of malignancy within the ipmns.


Eligibility criteria:
inclusion criteria: * adult patients between the age of 18 and 90 years old who have been identified with a cystic mass consistent with ipmn on imaging exclusion criteria: * patients who formally decline enrolment into the study

Keywords: pancreatic cyst
to evaluate drug interactions between xnw3009, febuxostat, and colchicine in patients with gout

Conditions: Gout

Summary: a single-center, open-access study to evaluate drug interactions between xnw3009, febuxostat, and colchicine in patients with gout


Eligibility criteria:
inclusion criteria: * subject has a body mass index ≥18.0 and ≤32 kg/m2; * screening sua value ≥480μmol/l; * subject has no clinically relevant abnormalities in vital signs, ecg, physical examination，imaging examination or safety laboratory values. exclusion criteria: * subject known or suspected of being sensitive to the study drugs or its ingredient；scr\>uln； * history of kidney stones or screening kidney stones by b-ultrasound; * history of malignancy； * history of xanthinuria； * donated blood（≥400ml）within 3 months prior to screening or received transfusion of blood * alt or ast \> 1.5 x uln * unstable angina, history of symptomatic arrhythmia, or heart failure * hbalc\>8% * egfr\<60ml/min/1.73m2 * investigational drug within 3 months of study dosing
lifestyle in pregnancy and offspring - comparison between children born to obese women and children born to normal weight women

Conditions: Childhood Obesity

Summary: children born to obese women are at risk of increased adiposity and later adverse metabolic outcomes. we have conducted a follow-up study on an existing clinical trial, called the lip study (lifestyle in pregnancy), registration number nct00530439,in which 360 obese pregnant women were randomized to either lifestyle intervention or routine obstetric care. this present study follows the children until 3 years of age. we have the hypothesis, that the intervention during pregnancy results in a lower degree of adiposity and metabolic risk factors in the offspring. clinical examination is taking place at age 2.5-3 years including anthropometric measurements, dual energy x-ray (dxa) scans and blood samples measuring metabolic markers.in addition, we have included an extra control group of children born to normal weight women, who were not part of a lifestyle intervention program during pregnancy. we have the hypothesis that the children of the normal weight women have a better metabolic profile than the children born to the obese women.


Eligibility criteria:
inclusion criteria: - all children born to obese women who participated in the lip study (a randomized controlled trial of lifestyle intervention during pregnancy) and children born at term to healthy women with a normal pregestational bmi. exclusion criteria: - the children born to normal weight women only: preterm birth, congenital anomalies, maternal gestational diabetes, maternal diabetes mellitus, severe medical conditions in either child or mother.

Keywords: childhood adiposity metabolic risk factors bone mineralization
study of nitazoxanide, peginterferon alfa-2a and ribavirin in treatment-naive hepatitis c patients

Conditions: Chronic Hepatitis C

Summary: the purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis c in treatment-naive patients.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c genotype 1. exclusion criteria: * patients that have previously received treatment with any interferon or interferon-based treatment for chronic hepatitis c. * females of child-bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active. * males whose female partners are either pregnant or of child-bearing potential or not using birth control and are sexually active. * other causes of liver disease including autoimmune hepatitis. * transplant recipients receiving immune suppression therapy. * screening tests positive for anti-hepatitis a virus immunoglobulin m antibody (anti-hav igm ab), hepatitis b's antigen (hbsag), anti-hepatitis b core immunoglobulin m antibody (anti-hbc igm ab) or anti-human immunodeficiency virus antibody (anti-hiv ab). * decompensated cirrhosis, history of variceal bleeding, ascites, hepatic encephalopathy, child-turcotte-pugh (ctp) score \>6 or model for end-stage liver disease (meld) score \>8. * alcohol consumption of \>40 grams per day or an alcohol use pattern that will interfere with the study. * absolute neutrophil count \<1500 cells/mm3; platelet count \<135,000 cells/mm3; hemoglobin \<12 g/dl for women and \<13 g/dl for men; or serum creatinine concentration ≥1.5 times upper limit of normal (uln). * hypothyroidism or hyperthyroidism not effectively treated with medication. * hemoglobin a1c (hgba1c) \>7.5 or history of diabetes mellitus. * body mass index (bmi) \>34. * history or other clinical evidence of significant or unstable cardiac disease. * history or other clinical evidence of chronic pulmonary disease associated with functional impairment. * serious or severe bacterial infection(s). * ulcerative or hemorrhagic/ischemic colitis. * pancreatitis. * history of severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization. * history of uncontrolled severe seizure disorder. * requires concomitant theophylline or methadone. * history of immunologically mediated disease requiring more than intermittent anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids. * history or other evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension. * hemoglobinopathies. * history of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectable solution or ribavirin tablets.

Keywords: hepatitis c, chronic
pyrotinib plus trastuzumab after first-line th (p) treatment with her-2 positive breast cancer

Conditions: Advanced Breast Cancer

Summary: the purpose of this study is to assess the effect of pyrotinib

the purpose of this study is to assess the effect of pyrotinib combined with trastuzumab in the maintenance phase delay/reduction of brain metastases after first-line th(p) therapy for her-2-positive advanced breast cancer

Eligibility criteria:
inclusion criteria: 1. age:18-75 years old, female; 2. her2 positive advanced breast cancer diagnosed by pathology, cytology or radiology, including inoperable breast cancer with stage iv, or recurrent/metastatic breast cancer.her-2 positivity was confirmed by histopathological test: immunohistochemistry(ihc) results of 3 + or in situ hybridization (ish) results of amplification of her2; 3. disease progression occurs after treatment with trastuzumab (stopping the drug for more than 12 months) or newly diagnosed iv stage breast cancer patients; 4. eastern cooperative oncology group (ecog) performance status of 0-1; 5. life expectancy greater than or equal to 6 months; 6. the main organs function well, and the inspection indicators meet the following requirements: 1) for results of blood routine test hb≥90g/l; anc≥1.5×109/l; plt≥90×109/l; 2) for results of blood biochemical test alt and ast≤2×uln, but≤5×uln if the transferanse elevation is due to liver metastases； tbil≤1.5×uln； serum creatinine ≤1.5×uln; 7. the researchers believed that the subjects were preference to benefit; 8. participants were willing to join in this study, and written informed consent. exclusion criteria: 1. patients with brain metastases by ct or mri; 2. more factors affecting of oral drugs (gastrointestinal surgery history, inability to swallow, chronic diarrhea, intestinal obstruction); 3. study drug and excipient allergy; 4. history of psychiatric drugs abuse and can't quit or patients with mental disorders; 5. pregnant or lactating female patients; 6. less than 4 weeks from the last clinical trial; 7. the researchers think inappropriate.

Keywords: pyrotinib;cns;breast cancer; her-2 positivity
effects of systematic patient feedback on therapy outcome

Conditions: Mental Disorders

Summary: the aim of this study is to evaluate the effects of a feedback-system in psychotherapy on adult out-patients at a community mental health centre. it is hypothesized that the intervention will lead to more effective treatment, decreasing treatment dropout as well as improving patient-therapist relationship and patient activation in treatment.


Eligibility criteria:
the aim is to include a total of 128 patients. inclusion criteria: * referred for treatment of mental disorder(s) exclusion criteria: * psychiatric emergency * poor/no understanding of norwegian language * lack of ability to execute the practical procedures required for the project

Keywords: community mental health services psychotherapy physician-patient relations norway
diphenoxylate / atropine to decrease fdg activity during f-18 fdg pet

Conditions: Lymphoma

Summary: 2-\[18f\]-fluoro-2-deoxyd-glucose positron emission tomography (fdg pet) has proven to be a valuable clinical tool for the staging and surveillance of lymphoma.1-6 occasionally, lymph nodes in the mesentery and retroperitoneum can be difficult to distinguish from normal bowel activity on pet scans despite three-plane and cine maximal image projection (mip) imaging. this uncertainty limits the clinical usefulness of pet in some cases of lymphoma.7-8 in addition, bowel activity can also hinder interpretation of pet scans in other types of solid tumors including melanoma and colorectal cancer.6,9,10 our goal is to determine how well diphenoxylate/atropine 5mg/0.05mg (lomotil) decreases bowel activity and how this decrease impacts clinical decision-making, specifically for lymphoma staging and surveillance. this is a prospective, randomized, double-blinded study involving 60 patients undergoing pet scans for newly diagnosed or recurrent, untreated lymphoma.


Eligibility criteria:
inclusion criteria * males and females 18 years of age or older * subjects pre-scheduled for clinically-indicated pet scan * subjects with newly diagnosed or recurrent untreated disease (lymphoma) based on abdominal and/or pelvic adenopathy or masses on ct within 6 months of pet scan exclusion criteria * allergy to lomotil (diphenoxylate hydrochloride, atropine sulfate) * subjects with one or more episodes of diarrhea within 24 hours prior to pet scan * women who are breast-feeding * subjects with a history of severe liver disease, jaundice, dehydration, or narrow-angle glaucoma
tetracycline versus doxycycline for hp rescue therapy

Conditions: Helicobacter Pylori Infection

Summary: this randomized controlled clinical trial will evaluate the efficacy and safety of proton pump inhibitor, bismuth, metronidazole, and either tetracycline or doxycycline for helicobacter pylori rescue treatment. the completion of this trial will expand new therapy for the treatment of helicobacter pylori.


Eligibility criteria:
inclusion criteria: * participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (icf). * 18-75 years old on the day of signing the icf. * helicobacter pylori infection confirmed by 13c-urea breath test or rapid urease test. * have failed eradication treatment before. exclusion criteria: * have not received hp eradication treatment. * patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases. * subjects or guardians refused to participate in the trial. * alcohol and/or drugs abuse (addiction or dependence) or poor compliance with doctor's judgment. * have taken antibiotics, bismuth, ppi or chinese traditional medicine 4 weeks before treatment. * pregnant or lactating women. * active peptic ulcer. * allergic to drugs used in the trial. * any other circumstances that are not suitable for recruitment.
positions and peripheral oxygen saturation

Conditions: Lung Diseases

Summary: the subjects were placed consecutively in random order in the five different positions by drawing lots. oxygen saturation (sao2) and vital signs (pulse rate, respiratory rate, systolic blood pressure, diastolic blood pressure and body temperature) were measured in each position at 10, 25 and 40 minutes.

the semi-seated position in bed at 45°: sspb-45° the semi-seated position in bed at 60° :sspb-60° seated position in bed at 90°: spb-90° lying on the right side of the body at 45°: lrsb-45° , lying on the left side of the body at 45°: llsb-45° a questionnaire which consisted of a subjects' introduction form and a vital signs-sao2 record form was used in collecting the data. the subjects were placed consecutively in random order in the five different positions, sspb-45°, sspb-60°, spb-90°, lrsb-45°, and llsb-45°, by drawing lots. oxygen saturation (sao2) and vital signs (pulse rate, respiratory rate, systolic blood pressure, diastolic blood pressure and body temperature) were measured in each position at 10, 25 and 40 minutes. oxygen saturation and vital signs were measured with a finger pulse oximeter (nellcor n-560). nail polish was removed before measurement of oxygen saturation, and if there was any physical restraint on subjects it was removed. body temperature was measured via the ear with a tympanic membrane thermometer (covidiev genius 2). systolic and diastolic blood pressure were measured with a calibrated sphygmomanometer from the left arm with the same sphygmomanometer (erka aneroid sphygmomanometer®) and stethoscope. pulse rate and respiratory rate were manually monitored for a period of one minute by the researcher using a wristwatch. verbal and written informed consent was obtained from the subjects or from their closest relatives.

Eligibility criteria:
inclusion criteria: * subjects who were over 18 years of age and who are able to lie in all positions, and who had unilateral/or bilateral lung disease documented by medical diagnosis by a physician were included in this study. * patients who accepted to participated to the study. exclusion criteria: * patients who have not accepted to participate.

Keywords: patient positioning lung diseases oxygenation hemodynamic parameters vital signs
a study of lumigan® in patients with primary open angle glaucoma (poag) or ocular hypertension (oht)

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this is an observational study of lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with primary open angle glaucoma (poag) or ocular hypertension (oht).


Eligibility criteria:
inclusion criteria: * diagnosed with primary open angle glaucoma or ocular hypertension * prescribed lumigan® exclusion criteria: * none